Table 3.
Patterns of recurrence in HCC with Microvascular Invasion with and without adjuvant Lenvatinib.
| Parameters | Before PSM (n, %) | After PSM (n, %) | ||||
|---|---|---|---|---|---|---|
| No Lenvatinib (n = 236) | Lenvatinib (n = 57) | P | No Lenvatinib (n = 57) | Lenvatinib (n = 57) | P | |
| No. of recurrent cases | 124 (52.5) | 20 (35.1) | 0.026 | 31 (54.4) | 20 (35.1) | 0.059 |
| Time to recurrence, months* | 0.010 | 0.038 | ||||
| ≤12 | 94 (75.8) | 9 (45.0) | 24 (77.4) | 9 (47.3) | ||
| >12 | 30 (24.2) | 11 (55.0) | 7 (22.6) | 11 (52.7) | ||
| Type of recurrence** | 0.785 | 1.000 | ||||
| Intrahepatic | 104 (84.0) | 16 (80) | 24 (77.4) | 16 (80) | ||
| Extrahepatic | 8 (6.4) | 2 (10) | 4 (12.9) | 2 (10) | ||
| Intra- plus extrahepatic | 12 (9.6) | 2 (10) | 3 (10.7) | 2 (10) | ||
Bold values indicate statistical significance (P < 0.05). HCC, Hepatocellular Carcinoma; PSM, propensity score matching.